BACKGROUND: Dysregulated metabolism of bioactive sphingolipids, including ceramides and sphingosine-1-phosphate, has been implicated in cardiovascular disease, although the specific species, disease contexts, and cellular roles are not completely understood. Sphingolipids are produced by the serine palmitoyltransferase enzyme, canonically composed of 2 subunits, SPTLC1 (serine palmitoyltransferase long chain base subunit 1) and SPTLC2 (serine palmitoyltransferase long chain base subunit 2). Noncanonical sphingolipids are produced by a more recently described subunit, SPTLC3 (serine palmitoyltransferase long chain base subunit 3). METHODS: The noncanonical (d16) and canonical (d18) sphingolipidome profiles in cardiac tissues of patients with end-stage ischemic cardiomyopathy and in mice with ischemic cardiomyopathy were analyzed by targeted lipidomics. Regulation of SPTLC3 by HIF1α under ischemic conditions was determined with chromatin immunoprecipitation. Transcriptomics, lipidomics, metabolomics, echocardiography, mitochondrial electron transport chain, mitochondrial membrane fluidity, and mitochondrial membrane potential were assessed in the cSPTLC3(KO) transgenic mice we generated. Furthermore, morphological and functional studies were performed on cSPTLC3(KO) mice subjected to permanent nonreperfused myocardial infarction. RESULTS: Herein, we report that SPTLC3 is induced in both human and mouse models of ischemic cardiomyopathy and leads to production of atypical sphingolipids bearing 16-carbon sphingoid bases, resulting in broad changes in cell sphingolipid composition. This induction is in part attributable to transcriptional regulation by HIF1α under ischemic conditions. Furthermore, cardiomyocyte-specific depletion of SPTLC3 in mice attenuates oxidative stress, fibrosis, and hypertrophy in chronic ischemia, and mice demonstrate improved cardiac function and increased survival along with increased ketone and glucose substrate metabolism utilization. Depletion of SPTLC3 mechanistically alters the membrane environment and subunit composition of mitochondrial complex I of the electron transport chain, decreasing its activity. CONCLUSIONS: Our findings suggest a novel essential role for SPTLC3 in electron transport chain function and a contribution to ischemic injury by regulating complex I activity.
SPTLC3 Is Essential for Complex I Activity and Contributes to Ischemic Cardiomyopathy.
SPTLC3 对复合物 I 的活性至关重要,并导致缺血性心肌病
阅读:22
作者:Kovilakath Anna, Mauro Adolfo G, Valentine Yolander A, Raucci Frank J, Jamil Maryam, Carter Christiane, Thompson Jeremy, Chen Qun, Beutner Gisela, Yue Yang, Allegood Jeremy, Wang Xiaoxin X, Dail Jordan, Devarakonda Teja, Myakala Komuraiah, Windle Jolene J, Subler Mark A, Montefusco David, Willard Belinda, Javaheri Ali, Bernas Tytus, Mahata Sushil K, Levi Moshe, Liu Jinze, Porter George A Jr, Lesnefsky Edward J, Salloum Fadi N, Cowart L Ashley
| 期刊: | Circulation | 影响因子: | 38.600 |
| 时间: | 2024 | 起止号: | 2024 Aug 20; 150(8):622-641 |
| doi: | 10.1161/CIRCULATIONAHA.123.066879 | 研究方向: | 炎症/感染 |
| 疾病类型: | 心肌炎 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
